Publication: Comparison of methotrexate and Azathioprine as the first steroid-sparing immunosuppressive agent in patients with Takayasu's Arteritis
dc.contributor.coauthor | Kaymaz-Tahra, Sema | |
dc.contributor.coauthor | Tsechelidis, Ozun Bayindir | |
dc.contributor.coauthor | Ince, Burak | |
dc.contributor.coauthor | Isik, Ozlem Ozdemir | |
dc.contributor.coauthor | Kutu, Muhammet Emin | |
dc.contributor.coauthor | Karakas, Ozlem | |
dc.contributor.coauthor | Yildirim, Tuba Demirci | |
dc.contributor.coauthor | Ademoglu, Zeliha | |
dc.contributor.coauthor | Ediboglu, Elif Durak | |
dc.contributor.coauthor | Uludogan, Burcu Ceren Ekti | |
dc.contributor.coauthor | Ilgin, Can | |
dc.contributor.coauthor | Bilge, Sule Yasar | |
dc.contributor.coauthor | Kasifoglu, Timucin | |
dc.contributor.coauthor | Akar, Servet | |
dc.contributor.coauthor | Emmungil, Hakan | |
dc.contributor.coauthor | Onen, Fatos | |
dc.contributor.coauthor | Omma, Ahmet | |
dc.contributor.coauthor | Yazici, Ayten | |
dc.contributor.coauthor | Cefle, Ayse | |
dc.contributor.coauthor | Inanc, Murat | |
dc.contributor.coauthor | Aksu, Kenan | |
dc.contributor.coauthor | Keser, Gokhan | |
dc.contributor.coauthor | Direskeneli, Haner | |
dc.contributor.coauthor | Alibaz-Oner, Fatma | |
dc.contributor.department | School of Medicine | |
dc.contributor.kuauthor | Kanıtez, Nilüfer Alpay | |
dc.contributor.schoolcollegeinstitute | SCHOOL OF MEDICINE | |
dc.date.accessioned | 2025-03-06T20:57:29Z | |
dc.date.issued | 2023 | |
dc.description.abstract | Background Conventional disease-modifying anti-rheumatic drugs (cDMARDs) are recommended in addition to glucocorticoids (GC) for all active Takayasu's arteritis (TAK) patients as the first-line therapy.However, there is limited data comparing cDMARDs as the first-line immunosuppressive (IS) treatment. Objectives In this study, we aimed to compare the outcomes of methotrexate (MTX) and azathioprine (AZA), which were used most frequently as the first-line cDMARDs in TAK patients. | |
dc.description.indexedby | WOS | |
dc.description.publisherscope | International | |
dc.description.sponsoredbyTubitakEu | N/A | |
dc.identifier.eissn | 2326-5205 | |
dc.identifier.issn | 2326-5191 | |
dc.identifier.quartile | Q1 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14288/27252 | |
dc.identifier.volume | 75 | |
dc.identifier.wos | 1190014303066 | |
dc.keywords | Takayasu’s arteritis | |
dc.keywords | Biologic immunosuppressive treatment | |
dc.keywords | Patient characteristics | |
dc.keywords | Follow-up | |
dc.keywords | Daily practice | |
dc.keywords | Biologic therapy | |
dc.keywords | Treatment selection | |
dc.keywords | Arteritis management | |
dc.keywords | Immunosuppressive therapy | |
dc.keywords | Chronic disease management | |
dc.language.iso | eng | |
dc.publisher | Wiley | |
dc.relation.ispartof | ARTHRITIS and RHEUMATOLOGY | |
dc.subject | Rheumatology | |
dc.title | Comparison of methotrexate and Azathioprine as the first steroid-sparing immunosuppressive agent in patients with Takayasu's Arteritis | |
dc.type | Other | |
dc.type.other | Meeting abstract | |
dspace.entity.type | Publication | |
local.contributor.kuauthor | Kanıtez, Nilüfer Alpay | |
local.publication.orgunit1 | SCHOOL OF MEDICINE | |
local.publication.orgunit2 | School of Medicine | |
relation.isOrgUnitOfPublication | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isOrgUnitOfPublication.latestForDiscovery | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isParentOrgUnitOfPublication | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e | |
relation.isParentOrgUnitOfPublication.latestForDiscovery | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e |